Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neuroblastoma 2Pancreatic Neoplasms 1Neoplasms 1Melanoma 1Lung Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia 1

Interventions

Ipilimumab 106Nivolumab 101pembrolizumab 90aldesleukin 72Cyclophosphamide 46Interleukin-2 45Temozolomide 36Dacarbazine 32trametinib 31dabrafenib 30fludarabine phosphate 29incomplete Freund's adjuvant 27Bevacizumab 26sargramostim 25Vemurafenib 25fludarabine 22binimetinib 21Radiosurgery 21Paclitaxel 20encorafenib 19Carboplatin 19CTLA-4 Antigen 18cobimetinib 16atezolizumab 15Radiotherapy 14Biopsy 14Sorafenib 13MART-1 Antigen 12talimogene laherparepvec 11montanide ISA 51 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Melanoma × saponin QA-21V1 × Clear all
NCT00003362 2013-06-25

Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡